If you have patients with GIST who are looking for options, you may want to consider referring them to the invictus study.
The invictus study is a Phase 3 clinical research study to assess the safety and efficacy of the investigational drug, DCC-2618, in patients with advanced GIST who have received prior anticancer treatment. Key study eligibility criteria include:
Approximately 120 eligible patients will be randomized 2:1 to receive either DCC-2618 (150 mg) or placebo once daily by mouth. Upon disease progression, patients will be given options to change their study treatment: Those receiving DCC-2618 may increase their dose to 150 mg BID, and those receiving placebo may cross over to begin receiving DCC-2618 150 mg QD. Patients will be eligible to receive DCC-2618 for up to 2 years or until commercial supply is available. All patients will be required to attend study visits about once a month.
Please consider referring any potentially eligible patients for further evaluation.
For additional information about this study and how to refer a patient, please provide your contact information below. Thank you for your consideration.